Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results

Gastroenterology（2022）

引用 21|浏览22

暂无评分

摘要

SERENE UC confirms adalimumab is safe and effective in ulcerative colitis. Higher and standard induction dosing were similar and clinical remission was more frequently achieved with higher vs standard maintenance dosing.

查看译文

关键词

Adalimumab,Monoclonal Antibody,Inflammatory Bowel Disease,Moderately to Severely Active Ulcerative Colitis,Clinical Trial Result

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要